Prevalence of COVID-19 in patients with autoimmune liver disease in Europe: A patient-oriented online survey.
Adolescent
Adult
Aged
Aged, 80 and over
COVID-19
/ epidemiology
Child
End Stage Liver Disease
/ epidemiology
Europe
/ epidemiology
Female
Hepatitis, Autoimmune
/ epidemiology
Humans
Liver Cirrhosis
/ epidemiology
Liver Transplantation
Male
Middle Aged
Prevalence
Registries
SARS-CoV-2
Severity of Illness Index
Surveys and Questionnaires
Young Adult
(AILD)
COVID-19
Europe
SARS-CoV-2
advanced liver disease
autoimmuneliver disease
chronic liver disease
incidence
online survey
prevalence
Journal
United European gastroenterology journal
ISSN: 2050-6414
Titre abrégé: United European Gastroenterol J
Pays: England
ID NLM: 101606807
Informations de publication
Date de publication:
09 2021
09 2021
Historique:
received:
10
01
2021
accepted:
29
03
2021
pubmed:
10
6
2021
medline:
4
2
2022
entrez:
9
6
2021
Statut:
ppublish
Résumé
During the current SARS-CoV-2 pandemic it is important to identify risk factors for COVID-19. Registry studies are providing growing evidence on the elevated risk of mortality from COVID-19 in patients with chronic liver disease, especially in advanced stages. Results may, however, have a selection bias towards severe cases. Limited data is available on COVID-19 in patients with autoimmune liver disease (AILD). To perform an online survey to capture the prevalence of COVID-19 and the state of medical care of patients with AILD in Europe during the pandemic. Data was collected via an anonymous patient-oriented, online survey, which was available on the EUSurvey platform in nine European languages between 24 Of 1,779 participants, 1,752 resided in 20 different countries of the European Union and the United Kingdom (UK). The five countries with the highest numbers of contributions were France (n = 450), Germany (n = 318), the Netherlands (n = 267), Spain (n = 225), and the UK (n = 183). 2.2% of participants (39/1779) had been diagnosed with COVID-19. There were no differences regarding age, sex, AILD, the status of liver cirrhosis, or status post liver transplantation between COVID-19 and non-COVID-19 cases. Of the 39 COVID-19 cases, five patients were admitted to a regular ward, one patient was admitted to ICU and required ventilation. In our Europe-wide, patient-oriented survey on COVID-19 in patients with AILD, we detected a low rate of COVID-19, comparable to the period prevalence of the general population. These results suggest that patients with AILD are not at elevated risk of COVID-19.
Sections du résumé
BACKGROUND
During the current SARS-CoV-2 pandemic it is important to identify risk factors for COVID-19. Registry studies are providing growing evidence on the elevated risk of mortality from COVID-19 in patients with chronic liver disease, especially in advanced stages. Results may, however, have a selection bias towards severe cases. Limited data is available on COVID-19 in patients with autoimmune liver disease (AILD).
AIM
To perform an online survey to capture the prevalence of COVID-19 and the state of medical care of patients with AILD in Europe during the pandemic.
METHODS
Data was collected via an anonymous patient-oriented, online survey, which was available on the EUSurvey platform in nine European languages between 24
RESULTS
Of 1,779 participants, 1,752 resided in 20 different countries of the European Union and the United Kingdom (UK). The five countries with the highest numbers of contributions were France (n = 450), Germany (n = 318), the Netherlands (n = 267), Spain (n = 225), and the UK (n = 183). 2.2% of participants (39/1779) had been diagnosed with COVID-19. There were no differences regarding age, sex, AILD, the status of liver cirrhosis, or status post liver transplantation between COVID-19 and non-COVID-19 cases. Of the 39 COVID-19 cases, five patients were admitted to a regular ward, one patient was admitted to ICU and required ventilation.
CONCLUSION
In our Europe-wide, patient-oriented survey on COVID-19 in patients with AILD, we detected a low rate of COVID-19, comparable to the period prevalence of the general population. These results suggest that patients with AILD are not at elevated risk of COVID-19.
Identifiants
pubmed: 34105883
doi: 10.1002/ueg2.12100
pmc: PMC8242670
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
797-808Subventions
Organisme : European Reference Network on Hepatological Diseases (ERN RARE-LIVER)
Informations de copyright
© 2021 The Authors. United European Gastroenterology Journal published by Wiley Periodicals LLC. on behalf of United European Gastroenterology.
Références
J Hepatol. 2017 Dec;67(6):1298-1323
pubmed: 28802875
N Engl J Med. 2021 Feb 25;384(8):693-704
pubmed: 32678530
PLoS One. 2020 Nov 3;15(11):e0241742
pubmed: 33141836
J Hepatol. 2012 May;56(5):1181-1188
pubmed: 22245904
J Hepatol. 2021 Jan;74(1):240-241
pubmed: 32918954
Lancet Gastroenterol Hepatol. 2020 Aug;5(8):724-725
pubmed: 32505228
Lancet Gastroenterol Hepatol. 2020 Nov;5(11):1008-1016
pubmed: 32866433
J Hepatol. 2014 Dec;61(6):1385-96
pubmed: 25135860
Clin Gastroenterol Hepatol. 2018 Feb;16(2):278-287.e7
pubmed: 28993258
Hepatology. 2013 Dec;58(6):2045-55
pubmed: 23775876
Ann Rheum Dis. 2020 Jul;79(7):859-866
pubmed: 32471903
J Hepatol. 2020 Sep;73(3):705-708
pubmed: 32446714
United European Gastroenterol J. 2021 Sep;9(7):797-808
pubmed: 34105883
J Gastroenterol Hepatol. 2003 Oct;18(10):1118-28
pubmed: 12974897
Infection. 2021 Apr;49(2):233-239
pubmed: 33034020
J Infect. 2020 Aug;81(2):e16-e25
pubmed: 32335169
J Hepatol. 2021 Jan;74(1):148-155
pubmed: 32750442
J Hepatol. 2020 Nov;73(5):1063-1071
pubmed: 32526252
J Hepatol. 2021 Mar;74(3):567-577
pubmed: 33035628
Gut. 2020 Oct;69(10):1832-1840
pubmed: 32571972
J Hepatol. 2021 Jun;74(6):1335-1343
pubmed: 33508378
Hepatol Commun. 2020 Jul 08;4(9):1257-1262
pubmed: 32838102
Gastroenterology. 2020 Aug;159(2):481-491.e3
pubmed: 32425234
Lancet. 2020 Feb 15;395(10223):497-506
pubmed: 31986264
J Hepatol. 2020 Sep;73(3):702-705
pubmed: 32413378
J Hepatol. 2012 Sep;57(3):675-88
pubmed: 22609307
Hepatol Int. 2020 Sep;14(5):690-700
pubmed: 32623632
Int J Infect Dis. 2020 May;94:91-95
pubmed: 32173574
Lancet Gastroenterol Hepatol. 2020 Jun;5(6):532-533
pubmed: 32278366